VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BAXBaxter International Inc.
$22.04$11.4B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksBAXFinancials

Baxter International Inc. (BAX) Financials

30Y historyFree accessUpdated daily

Revenue growth remains volatile amidst structural shifts, with gross margins experiencing significant compression from a 38.6% peak in 2024Q1 to 33.0% by 2026Q1.

BAX Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue11.32B11.24B10.64B10.36B10.06B12.15B11.67B11.36B11.1B10.58B10.16B9.97B10.72B9.41B13.94B13.89B12.84B12.56B12.35B11.26B10.38B9.85B9.51B8.9B8.1B7.36B6.7B6.38B5.71B5.26B5.44B
Revenue Growth %5.1%5.72%2.66%3.01%-17.2%4.05%2.74%2.37%4.87%4.14%1.96%-7.01%13.87%-32.46%0.31%8.18%2.24%1.73%9.63%8.53%5.37%3.58%6.79%9.94%10.1%9.84%4.97%11.81%8.5%-3.29%7.73%
Cost of Goods Sold7.91B7.87B6.65B6.21B6.51B7.43B7.09B6.6B6.34B6.11B6.05B5.82B6.14B5.25B6.8B6.85B6.88B6.04B6.22B5.74B5.64B5.76B5.59B4.95B4.31B3.94B3.64B3.21B2.82B2.57B2.7B
COGS % of Revenue-69.95%62.54%59.94%64.71%61.14%60.7%58.1%57.12%57.73%59.5%58.41%57.26%55.78%48.81%49.28%53.61%48.06%50.36%51%54.36%58.44%58.83%55.6%53.27%53.62%54.37%50.39%49.35%48.87%49.6%
Gross Profit3.41B3.38B3.98B4.15B3.55B4.72B4.59B4.76B4.76B4.47B4.12B4.15B4.58B4.16B7.13B7.05B5.96B6.53B6.13B5.52B4.74B4.09B3.92B3.95B3.79B3.41B3.06B3.17B2.89B2.69B2.74B
Gross Margin %30.11%30.05%37.46%40.06%35.29%38.86%39.3%41.9%42.88%42.27%40.5%41.59%42.74%44.22%51.19%50.72%46.39%51.94%49.64%49%45.64%41.56%41.17%44.4%46.73%46.38%45.63%49.61%50.65%51.13%50.4%
Gross Profit Growth %--15.19%-4%16.93%-24.81%2.9%-3.65%0.04%6.37%8.7%-0.72%-9.5%10.07%-41.66%1.25%18.26%-8.69%6.44%11.07%16.51%15.73%4.55%-0.96%4.44%10.93%11.65%-3.44%9.52%7.47%-1.9%6.28%
Operating Expenses3.71B3.69B3.97B3.44B6.39B3.37B2.97B2.99B3.17B3.19B3.37B3.7B3.92B3.67B4.31B4.1B3.82B3.65B3.57B3.35B2.9B2.45B3.02B2.69B2.26B2.19B2.02B2.02B1.88B1.8B1.83B
OpEx % of Revenue-32.79%37.33%33.23%63.58%27.75%25.45%26.31%28.61%30.1%33.17%37.09%36.62%38.95%30.95%29.51%29.76%29.04%28.88%29.75%27.91%24.92%31.76%30.27%27.86%29.76%30.19%31.58%32.86%34.27%33.65%
Selling, General & Admin2.92B2.89B2.97B2.95B3.1B2.85B2.47B2.54B2.62B2.63B2.73B3.09B3.31B3.08B3.28B3.15B2.91B2.73B2.7B2.52B2.28B2.03B1.96B1.8B1.57B1.44B1.33B1.31B1.21B1.15B1.14B
SG&A % of Revenue-25.7%27.9%28.5%30.79%23.42%21.15%22.31%23.61%24.82%26.81%31.04%30.93%32.76%23.56%22.7%22.63%21.74%21.85%22.38%21.99%20.61%20.61%20.27%19.34%19.58%19.86%20.55%21.17%21.77%21%
Research & Development517M518M590M518M450M531M521M595M654M615M646M603M610M582M1.08B946M915M917M868M760M614M533M517M553M501M426M378M332M323M339M340M
R&D % of Revenue-4.61%5.55%5%4.47%4.37%4.46%5.24%5.89%5.81%6.36%6.05%5.69%6.18%7.76%6.81%7.12%7.3%7.03%6.75%5.92%5.41%5.44%6.21%6.19%5.79%5.64%5.2%5.66%6.45%6.25%
Other Operating Expenses-2M279M413M-28M2.85B-6M-19M-141M-99M-56M0000-51M000070M0-109M543M337M189M323M314M372M344M318M348M
Operating Income-300M-308M14M707M-2.85B1.35B1.62B1.77B1.58B1.29B745M449M656M496M2.82B2.95B2.14B2.88B2.56B2.17B1.84B1.64B895M1.26B1.53B1.22B1.03B1.15B1.01B887M911M
Operating Margin %-2.65%-2.74%0.13%6.82%-28.29%11.11%13.84%15.6%14.27%12.17%7.33%4.5%6.12%5.27%20.24%21.2%16.63%22.9%20.76%19.25%17.74%16.64%9.41%14.13%18.88%16.63%15.44%18.03%17.79%16.87%16.75%
Operating Income Growth %--2300%-98.02%124.85%-310.74%-16.46%-8.8%11.87%22.98%72.89%65.92%-31.55%32.26%-82.42%-4.24%37.92%-25.76%12.21%18.27%17.76%12.32%83.13%-28.86%-17.72%25.02%18.28%-10.09%13.3%14.43%-2.63%11.92%
EBITDA671M673M1.01B1.69B-1.77B2.22B2.44B2.56B2.35B2.04B1.54B1.21B1.45B1.13B3.53B3.62B2.82B3.52B3.19B2.75B2.42B2.22B1.5B1.8B1.97B1.65B1.43B1.52B1.36B1.21B1.26B
EBITDA Margin %5.93%5.99%9.51%16.32%-17.63%18.25%20.89%22.54%21.22%19.26%15.2%12.12%13.51%12.02%25.35%26.03%21.97%27.98%25.87%24.41%23.28%22.53%15.73%20.25%24.3%22.43%21.32%23.86%23.82%22.91%23.15%
EBITDA Growth %-27.85%-33.43%-40.21%195.38%-179.97%-9.1%-4.76%8.75%15.55%31.91%27.9%-16.57%28.03%-67.99%-2.3%28.18%-19.74%10.02%16.22%13.78%8.88%48.33%-17.03%-8.38%19.27%15.55%-6.18%11.99%12.78%-4.29%9.48%
D&A (Non-Cash Add-back)971M981M997M984M1.07B867M823M789M771M750M800M759M792M635M712M670M685M638M631M581M575M580M601M545M439M427M394M372M344M318M348M
EBIT-227M-215M119M750M-2.83B1.32B1.45B1.08B1.71B1.19B5.04B574M657M530M2.95B2.9B2B2.85B2.61B2.24B1.84B1.53B1.44B1.59B1.72B1.5B1.32B1.15B1.01B887M911M
Net Interest Income-240M-238M-341M-439M-394M-193M-134M-71M-45M-55M-66M-126M-145M-128M-87M-54M-87M-98M-76M-22M-101M-118M-99M-115M-71M-108M-131M0-193M0-214M
Interest Income35M52M67M69M19M14M19M40M48M30M23M20M22M27M26M38M28M19M72M102M00000000000
Interest Expense275M290M408M508M413M207M153M111M93M85M89M146M167M155M113M92M115M117M148M124M101M118M99M115M71M108M131M0193M0214M
Other Income/Expense-208M-197M-303M-465M-403M-234M-324M-802M33M-188M4.21B-21M-166M-121M17M-137M-246M-143M-102M-54M-95M-195M-465M-129M-143M-244M-72M-98M-522M-317M-118M
Pretax Income-508M-505M-289M242M-3.25B1.12B1.29B970M1.62B1.1B4.95B428M490M375M2.84B2.81B1.89B2.73B2.46B2.11B1.75B1.44B430M1.13B1.39B979M962M1.05B493M570M793M
Pretax Margin %-4.49%-4.49%-2.72%2.34%-32.3%9.19%11.07%8.54%14.57%10.39%48.75%4.29%4.57%3.98%20.36%20.22%14.72%21.76%19.94%18.77%16.82%14.66%4.52%12.68%17.11%13.31%14.36%16.49%8.64%10.84%14.58%
Income Tax473M395M37M61M-135M83M182M-41M65M491M-12M35M33M60M555M553M463M519M437M407M348M486M47M222M360M304M208M273M218M199M218M
Effective Tax Rate %-93.11%-78.22%-12.8%25.21%4.16%7.44%14.09%-4.23%4.02%44.64%-0.24%8.18%6.73%16%19.56%19.69%24.5%18.98%17.75%19.25%19.93%33.66%10.93%19.66%25.97%31.05%21.62%25.95%44.22%34.91%27.49%
Net Income-1.1B-957M-649M2.66B-2.43B1.28B1.1B1B1.55B602M4.96B968M2.5B2.01B2.33B2.22B1.42B2.21B2.01B1.71B1.4B956M388M866M771M612M740M797M315M300M669M
Net Margin %-9.7%-8.51%-6.1%25.64%-24.19%10.57%9.44%8.81%13.93%5.69%48.85%9.71%23.3%21.37%16.69%16.01%11.06%17.55%16.31%15.16%13.45%9.71%4.08%9.73%9.52%8.32%11.05%12.49%5.52%5.7%12.3%
Net Income Growth %-96.07%-47.46%-124.44%209.17%-289.49%16.52%10.09%-35.25%156.81%-87.88%412.91%-61.23%24.11%-13.5%4.59%56.62%-35.6%9.48%17.98%22.28%46.03%146.39%-55.2%12.32%25.98%-17.3%-7.15%153.02%5%-55.16%3.08%
Net Income (Continuing)-981M-900M-326M181M-3.11B1.03B1.11B1.01B1.55B609M4.97B393M457M315M2.28B2.26B1.43B2.21B2.02B1.71B1.4B958M383M907M1.03B675M754M779M275M371M575M
Discontinued Operations0-57M-312M2.48B692M262M00-6M-7M-1M575M2.04B1.7B43M00000-1M-2M5M-24M-255M-11M-14M45M40M-71M94M
Minority Interest-27M-27M60M66M62M44M37M30M22M-8M-10M19M36M23M40M243M229M229M0000000000000
EPS (Diluted)-2.13-1.75-1.275.23-4.832.532.131.932.971.089.011.764.563.664.183.882.393.593.162.612.131.520.631.501.661.091.251.350.550.531.23
EPS Growth %-92.61%-37.8%-124.28%208.28%-290.91%18.78%10.36%-35.02%175%-88.01%411.93%-61.4%24.59%-12.44%7.73%62.34%-33.43%13.61%21.07%22.54%40.13%141.27%-58%-9.64%52.29%-12.8%-7.41%145.45%3.77%-56.91%4.24%
EPS (Basic)--1.75-1.275.25-4.832.562.171.973.041.119.091.784.613.704.223.912.413.633.222.652.151.540.631.511.711.131.271.380.560.541.23
Diluted Shares Outstanding515M513M510M506M504M508M517M519M546M555M551M549M547M549M556M573M594M614M637M654M656M629M618M577.33M464.46M561.47M592M590M578M564M552M
Basic Shares Outstanding515M513M510M506M504M502M509M509M534M543M546M545M542M543M551M569M590M607M625M644M651M622M614M573.51M450.88M541.59M582.68M580M568M556M544M
Dividend Payout Ratio---22.06%-41.28%42.92%42.26%24.32%52.33%5.4%94.01%43.85%50.84%34.57%31.88%48.45%28.66%27.11%41.24%-----------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetStrained
Cash FlowDeteriorating
Top Statement Risk

Portfolio transformation execution risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Amidst Structural Transition

According to recent financial disclosures, Baxter's revenue growth has exhibited significant volatility, with quarterly figures fluctuating between a 29.1% contraction in 2024 and an 8.0% expansion by 2025Q4, reflecting the ongoing impact of divestitures and the complex integration of the Hillrom acquisition into core operations.

The inconsistent revenue trajectory suggests that the company is struggling to establish a stable organic growth baseline while navigating the Vantive spin-off. Investors should monitor whether the recent return to positive growth in late 2025 represents a sustainable recovery or merely a temporary stabilization following aggressive portfolio pruning.

Gross Margin Compression and Volatility

As reported in quarterly income statements, Baxter's gross margins have faced substantial pressure, plummeting from a peak of 38.6% in early 2024 to a low of 19.4% in 2025Q4, indicating significant challenges in managing input costs and maintaining pricing power within its medical device segments.

The sharp contraction in gross margins suggests that inflationary pressures on raw materials and logistics are disproportionately impacting the company's high-volume consumable business. This volatility warrants further investigation into whether the current margin profile is a structural impairment or a transient result of supply chain realignment.

Earnings Quality Obscured by Charges

Based on reported figures, Baxter's net income has been frequently marred by significant non-operating items and restructuring charges, resulting in erratic EPS performance that swung from a $0.48 profit in 2023Q4 to a $2.16 loss per share by the end of 2025.

The frequent divergence between operating income and net income suggests that the company's underlying earnings power is being masked by persistent transformation costs. Analysts should be wary of relying on headline EPS, as the recurring nature of these charges implies that the company's profitability remains fundamentally strained.

Structural Risks to Margin Recovery

Evidence from recent filings suggests that Baxter's reliance on low-margin consumables, combined with a high fixed-cost base, creates a precarious environment where even minor operational disruptions lead to significant operating margin compression, as evidenced by the negative 2.74% operating margin reported in recent periods.

Short-sellers may focus on the company's inability to scale operating income despite revenue growth, which suggests that the current business model lacks the necessary operating leverage. The ongoing portfolio transformation may not be sufficient to offset the structural headwinds facing the company's legacy product lines.

BAX — Frequently Asked Questions

Quick answers to the most common questions about buying BAX stock.

What was Baxter International Inc.'s (BAX) revenue in 2025?

For fiscal year 2025, Baxter International Inc. (BAX) reported total revenue of $11.24B. This represents a 106.8% increase compared to $5.44B in 1996.

Is Baxter International Inc. (BAX) profitable?

Baxter International Inc. (BAX) reported a net loss of $957.0M for the fiscal year ending 2025.

What is Baxter International Inc.'s operating profit margin?

Baxter International Inc. (BAX) reported an operating income of $-308.0M, resulting in an operating profit margin of -2.7%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Baxter International Inc.'s gross profit and gross margin?

Baxter International Inc. (BAX) generated $3.38B in gross profit for the year, representing a gross profit margin of 30.1%. This demonstrates the company's core pricing power and production efficiency.